Binkow & Goldberg LLP announces that it is investigating
potential claims on behalf of investors of Impax
Laboratories, Inc. ("Impax" or the "Company") (NASDAQ:IPXL)
concerning possible violations of federal securities laws. The
investigation focuses on certain statements issued by the Company
concerning Impax's business and financial prospects.
Please contact Casey
Sadler, Esquire, at (888) 773-9224 or (310) 201-9150, or at email@example.com
to discuss this matter. If you inquire by email please include your
mailing address, telephone number and number of shares purchased.
Impax, a specialty pharmaceutical company, develops, manufactures and
markets bioequivalent pharmaceutical products, and develops and markets
branded products. The investigation relates to the Company's July 29,
2014, disclosure that the Food and Drug Admission ("FDA") had uncovered
potential issues at a facility where the Company would manufacture
Rytary, its experimental Parkinson's disease drug. According to the
Company, the FDA wants Impax to address a variety of issues at the
facility, including problems with equipment, sample testing, rejection
of drugs that do not meet the Company's manufacturing standards, and
procedures designed to keep microorganisms out of some products. On this
news, shares of Impax declined $4.27 per share, 15.23%, to close on July
29, 2014, at $23.76 per share, on unusually heavy volume.
If you purchased shares of Impax, if you have information or would like
more about these claims, or if you have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Casey
Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park
East, Suite 2100, Los Angeles, California 90067, by toll-free telephone
at (888) 773-9224 or by telephone at (310) 201-9150, by e-mail to firstname.lastname@example.org,
or visit our website at http://www.glancylaw.com.
If you inquire by email, please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
[ Back To NFVZone's Homepage ]